Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080180212> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W3080180212 abstract "Introduction Prostate cancer (PCa) is the most common male genitourinary malignancy in the world. The protein arginine methyltransferase 5 (PRMT5) is one of the main members of the type II PRMT family, which was reported to regulate androgen-dependent PCa cell proliferation. However, the upstream regulators of PRMT5 and its effects on androgen-independent PCa metastasis remained unclear. In the present study, we investigated whether PRMT5 could be a novel diagnostic marker and be used as a therapeutic target in PCa, to explore the possible molecular mechanism, and to understand the clinical importance of PRMT5 in PCa. Material and methods The present study evaluated PRMT5 expression levels in PCa and normal prostate samples using public datasets, including TCGA, GEPIA and GSE21032. Furthermore, CCK-8 assay, flow cytometer assay, and transwell assay were conducted to detect the roles of PRMT5. Luciferase reporter assay was used to determine the relationship among ZFAS1/miR-150-5p/PRMT5. Results Our results showed that PRMT5 was overexpressed in PCa samples. PRMT5 significantly promoted androgen-dependent PCa proliferation and cell cycle progression and suppressed cell apoptosis. However, PRMT5 did not affect androgen-independent PCa proliferation but it could significantly induce androgen-independent PCa metastasis. Knockdown of PRMT5 suppressed, whereas overexpression of PRMT5 induced, cell migration and invasion in androgen-independent DU145 and PC-3 cells. Moreover, our results showed that the ZFAS1/miR-150-5p axis regulated PRMT5 expression in PCa cells. Furthermore, the study showed that ZFAS1 and PRMT5 were overexpressed and miR-150-5p was down-regulated in PCa samples. Higher expression levels of ZFAS1 and PRMT5 were correlated with shorter disease-free survival time in PCa patients. Conclusions These results showed that PRMT5 may be a therapeutic target for PCa." @default.
- W3080180212 created "2020-09-01" @default.
- W3080180212 creator A5035532824 @default.
- W3080180212 creator A5054268541 @default.
- W3080180212 creator A5069508144 @default.
- W3080180212 creator A5073216396 @default.
- W3080180212 creator A5074480744 @default.
- W3080180212 creator A5083228843 @default.
- W3080180212 date "2020-08-06" @default.
- W3080180212 modified "2023-09-26" @default.
- W3080180212 title "PRMT5, regulated by lncRNA ZFAS1/miR-150-5p, promoted androgen-independent prostate cancer migration and invasion" @default.
- W3080180212 doi "https://doi.org/10.5114/aoms.2020.97987" @default.
- W3080180212 hasPublicationYear "2020" @default.
- W3080180212 type Work @default.
- W3080180212 sameAs 3080180212 @default.
- W3080180212 citedByCount "0" @default.
- W3080180212 crossrefType "journal-article" @default.
- W3080180212 hasAuthorship W3080180212A5035532824 @default.
- W3080180212 hasAuthorship W3080180212A5054268541 @default.
- W3080180212 hasAuthorship W3080180212A5069508144 @default.
- W3080180212 hasAuthorship W3080180212A5073216396 @default.
- W3080180212 hasAuthorship W3080180212A5074480744 @default.
- W3080180212 hasAuthorship W3080180212A5083228843 @default.
- W3080180212 hasBestOaLocation W30801802121 @default.
- W3080180212 hasConcept C104317684 @default.
- W3080180212 hasConcept C111819275 @default.
- W3080180212 hasConcept C121608353 @default.
- W3080180212 hasConcept C126322002 @default.
- W3080180212 hasConcept C173396325 @default.
- W3080180212 hasConcept C190283241 @default.
- W3080180212 hasConcept C2780192828 @default.
- W3080180212 hasConcept C33288867 @default.
- W3080180212 hasConcept C502942594 @default.
- W3080180212 hasConcept C55493867 @default.
- W3080180212 hasConcept C62112901 @default.
- W3080180212 hasConcept C71924100 @default.
- W3080180212 hasConcept C86803240 @default.
- W3080180212 hasConcept C91965660 @default.
- W3080180212 hasConceptScore W3080180212C104317684 @default.
- W3080180212 hasConceptScore W3080180212C111819275 @default.
- W3080180212 hasConceptScore W3080180212C121608353 @default.
- W3080180212 hasConceptScore W3080180212C126322002 @default.
- W3080180212 hasConceptScore W3080180212C173396325 @default.
- W3080180212 hasConceptScore W3080180212C190283241 @default.
- W3080180212 hasConceptScore W3080180212C2780192828 @default.
- W3080180212 hasConceptScore W3080180212C33288867 @default.
- W3080180212 hasConceptScore W3080180212C502942594 @default.
- W3080180212 hasConceptScore W3080180212C55493867 @default.
- W3080180212 hasConceptScore W3080180212C62112901 @default.
- W3080180212 hasConceptScore W3080180212C71924100 @default.
- W3080180212 hasConceptScore W3080180212C86803240 @default.
- W3080180212 hasConceptScore W3080180212C91965660 @default.
- W3080180212 hasLocation W30801802121 @default.
- W3080180212 hasOpenAccess W3080180212 @default.
- W3080180212 hasPrimaryLocation W30801802121 @default.
- W3080180212 hasRelatedWork W2147269413 @default.
- W3080180212 hasRelatedWork W2465824079 @default.
- W3080180212 hasRelatedWork W2517461654 @default.
- W3080180212 hasRelatedWork W2593394863 @default.
- W3080180212 hasRelatedWork W2594015307 @default.
- W3080180212 hasRelatedWork W2908016561 @default.
- W3080180212 hasRelatedWork W3013460946 @default.
- W3080180212 hasRelatedWork W3185603359 @default.
- W3080180212 hasRelatedWork W3209052775 @default.
- W3080180212 hasRelatedWork W2987091734 @default.
- W3080180212 isParatext "false" @default.
- W3080180212 isRetracted "false" @default.
- W3080180212 magId "3080180212" @default.
- W3080180212 workType "article" @default.